MX2008009833A - Anticuerpo monoclonal anti-met, fragmentos y vectores del mismo para el tratamiento de tumores, y productos correspondientes. - Google Patents

Anticuerpo monoclonal anti-met, fragmentos y vectores del mismo para el tratamiento de tumores, y productos correspondientes.

Info

Publication number
MX2008009833A
MX2008009833A MX2008009833A MX2008009833A MX2008009833A MX 2008009833 A MX2008009833 A MX 2008009833A MX 2008009833 A MX2008009833 A MX 2008009833A MX 2008009833 A MX2008009833 A MX 2008009833A MX 2008009833 A MX2008009833 A MX 2008009833A
Authority
MX
Mexico
Prior art keywords
monoclonal antibody
tumors
vectors
treatment
met monoclonal
Prior art date
Application number
MX2008009833A
Other languages
English (en)
Inventor
Paolo Maria Comoglio
Elisa Vigna
Silvia Giordano
Original Assignee
Metheresis Translational Res S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metheresis Translational Res S filed Critical Metheresis Translational Res S
Publication of MX2008009833A publication Critical patent/MX2008009833A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/867—Retroviral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se describe el uso de un anticuerpo monoclonal dirigido contra el dominio extracelular del factor de crecimiento de hepatocitos, en la preparación de un medicamento para el tratamiento de tumores y/o metástasis y de una herramienta de diagnóstico para detectar células neoplásicas, así como vectores que comprenden por lo menos una porción de la secuencia de nucleótidos que codifica para el anticuerpo monoclonal anti-Met, productos que contienen el anticuerpo monoclonal anti-Met y/o al menos un fragmento del mismo y por lo menos un inhibidor de cinasa.
MX2008009833A 2006-02-06 2007-02-05 Anticuerpo monoclonal anti-met, fragmentos y vectores del mismo para el tratamiento de tumores, y productos correspondientes. MX2008009833A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06101345 2006-02-06
PCT/EP2007/051066 WO2007090807A1 (en) 2006-02-06 2007-02-05 Anti-met monoclonal antibody, fragments and vectors thereof, for the treatment of tumors and corresponding products

Publications (1)

Publication Number Publication Date
MX2008009833A true MX2008009833A (es) 2008-10-23

Family

ID=36616994

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2008009833A MX2008009833A (es) 2006-02-06 2007-02-05 Anticuerpo monoclonal anti-met, fragmentos y vectores del mismo para el tratamiento de tumores, y productos correspondientes.

Country Status (21)

Country Link
US (2) US8388958B2 (es)
EP (2) EP2192188A1 (es)
JP (1) JP5306828B2 (es)
KR (1) KR101429297B1 (es)
CN (1) CN101379192B (es)
AT (1) ATE514715T1 (es)
AU (1) AU2007213804B2 (es)
BR (1) BRPI0707480A8 (es)
CA (1) CA2638889C (es)
CY (1) CY1111884T1 (es)
DK (1) DK1981981T3 (es)
EA (1) EA015580B1 (es)
ES (1) ES2368864T3 (es)
IL (1) IL192879A (es)
MX (1) MX2008009833A (es)
PL (1) PL1981981T3 (es)
PT (1) PT1981981E (es)
SG (2) SG169382A1 (es)
SI (1) SI1981981T1 (es)
WO (1) WO2007090807A1 (es)
ZA (1) ZA200806559B (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2014681A1 (en) 2007-07-12 2009-01-14 Pierre Fabre Medicament Novel antibodies inhibiting c-met dimerization, and uses thereof
IL198545A0 (en) * 2008-05-14 2011-07-31 Metheresis Translational Res Sa High affinity binding site of hgfr and methods for identification of antagonists thereof
EP2127683A1 (en) * 2008-05-29 2009-12-02 Metheresis Translational Research SA Anti-Met monoclonal antibody, fragments and derivatives thereof for use in tumor imaging, corresponding compositions and kits
PA8849001A1 (es) 2008-11-21 2010-06-28 Lilly Co Eli Anticuerpos de c-met
EP2287197A1 (en) * 2009-08-21 2011-02-23 Pierre Fabre Medicament Anti-cMET antibody and its use for the detection and the diagnosis of cancer
KR101671378B1 (ko) * 2009-10-30 2016-11-01 삼성전자 주식회사 ｃ-Ｍｅｔ에 특이적으로 결합하는 항체 및 그의 용도
KR101748707B1 (ko) 2009-11-27 2017-06-20 삼성전자주식회사 ｃ-Ｍｅｔ에 특이적으로 결합하는 항체 및 그를 이용한 암 진단용 키트
SG10201501767VA (en) 2010-03-10 2015-05-28 Genmab As Monoclonal antibodies against c-met
EP2554993A4 (en) * 2010-04-02 2013-12-25 Fujirebio Kk MARKER FOR THE DIAGNOSIS OF THE EFFECT OF ANTICREMULATION
JP2013534515A (ja) * 2010-06-01 2013-09-05 モナシュ ユニバーシティ プロセシングされていない受容体型チロシンキナーゼｃ−ＭＥＴに対する抗体
AU2011296085A1 (en) * 2010-09-03 2013-03-28 Academia Sinica Anti-c-Met antibody and methods of use thereof
WO2012059562A1 (en) 2010-11-03 2012-05-10 Argen-X-Bv C-met antibody combinations
DK2500036T3 (da) * 2011-03-18 2014-08-04 Metheresis Translational Res Sa MET-hæmmere til øgning af virkningen af radioterapi
CA2843771A1 (en) 2011-09-20 2013-03-28 Eli Lilly And Company Anti-c-met antibodies
US9926364B2 (en) 2011-11-03 2018-03-27 Argen-X N.V. Chimeric human-llama antigens and methods of use
EP2782932A1 (en) 2011-11-21 2014-10-01 F.Hoffmann-La Roche Ag Purification of anti-c-met antibodies
US20150147274A1 (en) * 2011-12-02 2015-05-28 Cancer Research Technology Limited Antibodies against hgf - receptor and uses
US8900582B2 (en) 2011-12-22 2014-12-02 Samsung Electronics Co., Ltd. Deimmunized anti c-Met humanized antibodies and uses thereof
CN103382223B (zh) * 2012-04-01 2015-06-10 上海益杰生物技术有限公司 针对表皮生长因子受体隐蔽表位和t细胞抗原的多功能抗体多肽
HK1208181A1 (en) * 2012-06-21 2016-02-26 Sorrento Therapeutics, Inc. Antigen binding proteins that bind c-met
ITTO20130012A1 (it) 2013-01-09 2014-07-10 Metheresis Translational Res S A Nuovi frammenti anticorpali, relative composizioni ed usi
MX378108B (es) 2014-09-16 2025-03-10 Servier Lab Anticuerpos anti-met y composiciones.
WO2016149116A1 (en) * 2015-03-13 2016-09-22 University Of Maryland, Baltimore Antibodies targeting s100b and methods of use
US20180057595A1 (en) 2015-03-16 2018-03-01 Celldex Therapeutics, Inc. Anti-MET Antibodies and Methods of Use Thereof
GB201611123D0 (en) * 2016-06-27 2016-08-10 Euremab Srl Anti met antibodiesand uses thereof
IT201800000534A1 (it) * 2018-01-03 2019-07-03 Procedimenti per la promozione della crescita cellulare degli isolotti pancreatici.
CN116769033A (zh) * 2016-09-29 2023-09-19 田边三菱制药株式会社 cMET单克隆结合剂、其药物缀合物及其用途
TWI782930B (zh) 2016-11-16 2022-11-11 美商再生元醫藥公司 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
CN106872695B (zh) * 2017-01-20 2019-06-11 中山大学 一种h7亚型禽流感病毒血凝素抗体间接elisa检测试剂盒
IT201800000535A1 (it) 2018-01-03 2019-07-03 Procedimenti per la cura del cancro.
IT201800003875A1 (it) 2018-03-22 2019-09-22 Metis Prec Medicine Sb S R L Nuova combinazione di agenti terapeutici per il trattamento di un tumore e/o metastasi
JP7177848B2 (ja) 2018-03-28 2022-11-24 田辺三菱製薬株式会社 ｃＭＥＴモノクローナル結合剤の薬物複合体とその使用
IT201800009282A1 (it) 2018-10-09 2020-04-09 Metis Prec Medicine Sb Srl Nuovo agente terapeutico per il trattamento di un tumore e/o metastasi
CA3146933A1 (en) 2019-09-16 2021-03-25 Marcus KELLY Radiolabeled met binding proteins for immuno-pet imaging
WO2024246356A1 (en) 2023-06-01 2024-12-05 Pierre Fabre Medicament Silenced antibody-based anti-met constructs for the treatment of tumors and metastasis

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22545A1 (es) * 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
US6814962B1 (en) 1994-06-02 2004-11-09 Aventis Pharma S.A. Recombinant viruses and their use for treatment of atherosclerosis and other forms of coronary artery disease and method, reagent, and kit for evaluating susceptibility to same
US6214344B1 (en) * 1995-06-02 2001-04-10 Genetech, Inc. Hepatocyte growth factor receptor antagonists and uses thereof
HN2004000285A (es) * 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET

Also Published As

Publication number Publication date
SG169383A1 (en) 2011-03-30
JP5306828B2 (ja) 2013-10-02
CN101379192B (zh) 2013-07-31
US8388958B2 (en) 2013-03-05
ZA200806559B (en) 2012-12-27
DK1981981T3 (da) 2011-09-26
BRPI0707480A2 (pt) 2011-05-03
KR20090013745A (ko) 2009-02-05
PT1981981E (pt) 2011-10-04
SG169382A1 (en) 2011-03-30
PL1981981T3 (pl) 2011-11-30
EP1981981A1 (en) 2008-10-22
SI1981981T1 (sl) 2012-01-31
CY1111884T1 (el) 2015-11-04
AU2007213804A1 (en) 2007-08-16
KR101429297B1 (ko) 2014-08-12
WO2007090807A1 (en) 2007-08-16
BRPI0707480A8 (pt) 2022-11-08
US20120134996A1 (en) 2012-05-31
IL192879A0 (en) 2009-02-11
EA015580B1 (ru) 2011-10-31
ATE514715T1 (de) 2011-07-15
CN101379192A (zh) 2009-03-04
AU2007213804B2 (en) 2012-12-13
JP2009526010A (ja) 2009-07-16
US20090285807A1 (en) 2009-11-19
EP1981981B1 (en) 2011-06-29
EA200870234A1 (ru) 2009-02-27
ES2368864T3 (es) 2011-11-23
US8729043B2 (en) 2014-05-20
CA2638889A1 (en) 2007-08-16
AU2007213804A8 (en) 2008-08-28
EP2192188A1 (en) 2010-06-02
CA2638889C (en) 2015-06-02
IL192879A (en) 2014-02-27

Similar Documents

Publication Publication Date Title
SG169382A1 (en) Anti-met monoclonal antibody, fragments and vectors thereof, for the treatment of tumors and corresponding products
MX2012004258A (es) Inhibidores de la tirosina quinasa de bruton.
ZA200702973B (en) Disubstituted pyrazolobenzodiazepines useful as inhibitors for CDK2 and angiogesis, and for the treatment of breast, colon, lung and prostate cancer
PH12014500122A1 (en) Inhibitors of bruton's tyrosine kinase
EP4349868A3 (en) Humanized and chimeric monoclonal antibodies to cd47
MX2009008430A (es) Anticuerpos anti-robo4 y sus usos.
MX2010006823A (es) Metodos para el tratamiento de la gota.
MX2009012625A (es) Metodos para el tratamiento, diagnostico y deteccion de trastornos asociados con el fgf21.
NZ607710A (en) 4-1bb binding molecules
IL226717A (en) Isolated nucleic acids encoded by anti-beta human antibodies 7
ES2531093T3 (es) Procedimiento de preparación de halogenuros de N-alquil-naltrexona
WO2008034142A3 (en) Synthesis, methods of using, and compositions of cycloalkylmethylamines
WO2008011519A3 (en) Amigo-2 inhibitors for treating, diagnosing or detecting cancer
MX2009009816A (es) Anticuerpos monoclonales para el tratamiento del cancer.
WO2008061020A3 (en) Methods of treating, diagnosing or detecting cancer
TN2011000166A1 (en) Disubstituted phthalazine hedgehog pathway antagonists
NZ597531A (en) Inhibition of tumor metastasis using bv8- or g-csf-antagonists
TW200624426A (en) BACE inhibitors
UA99601C2 (ru) Применение антитела к cd151 для лечения первичных опухолей
WO2007120787A3 (en) Methods of treating, diagnosing or detecting cancers associated with liv-1 overexpression
WO2007107748A3 (en) Inhibition of tumour growth
ATE458487T1 (de) Tumorbehandlung mit gliotoxin-derivaten
WO2005076972A3 (en) Chimeric vegf peptides
WO2010148177A3 (en) Compounds, compositions, methods of synthesis, and methods of treatment
DK1869185T3 (da) Konjugat med P21-protein til kræftbehandling

Legal Events

Date Code Title Description
FG Grant or registration